This is the authors' abstract. We don't add key points for this paper.
recombinant human GLS1 enzyme activity assays successfully ruled out computational false positives and demonstrated that Compound 2 (quercetin) acts as the exclusive, direct enzymatic inhibitor among the tested monomers, capable of effectively suppressing GLS1 activity. Overall, this work provides a robust platform for real-time metabolic profiling of glutamine metabolism and drug screening at the living cell level, and offers new insights into the mechanisms of TCMs in anticancer therapy.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Lei et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: